VIRGO2/VISTA — Vaginal Microbiome 25-Type Precision Classification. Gardnerella Can Be Non-Inflammatory
SCIENCE

VIRGO2/VISTA — Vaginal Microbiome 25-Type Precision Classification. Gardnerella Can Be Non-Inflammatory

By Maya · · UMD School of Medicine / mBio
KO | EN

Women’s site-specific microbiome traditionally simplified: “Lactobacillus dominant = good, Gardnerella dominant = BV.” UMD School of Medicine mBio 2026.2 VIRGO2/VISTA toolchain proves this oversimplified. 25 precision types, including non-inflammatory Gardnerella-dominant forms.

Key Findings

VIRGO2/VISTA open-source toolchain:

  • Identifies 25 vaginal microbiome types
  • Strain-level (not species-level) distinction
  • Some Gardnerella-dominant = non-inflammatory profile (similar stability to Lactobacillus-dominant)
  • BV prevalence ~25% adult women

What is VIRGO2 / VISTA

VIRGO2 (Vaginal non-Redundant Gene Catalog v2): Vaginal microbiome gene catalog, 11,000+ genomes, metagenomic standard reference

VISTA (Vaginal microbiome SpecIes-level Taxonomy Analysis): Strain-level classification algorithm, open-source pipeline, automatic 25-type classification

25-Type Classification - New Paradigm

Existing (Ravel 2011):

  • CST I: L. crispatus dominant
  • CST II: L. gasseri dominant
  • CST III: L. iners dominant
  • CST IV: Diverse anaerobic (BV)
  • CST V: L. jensenii dominant

VIRGO2/VISTA 25 types:

  • CST IV split into 8~10 subtypes
  • Gardnerella species (G. vaginalis·swidsinskii·piotii·leopoldii) distinguished
  • Strain-level diversity within same species
  • Explains BV symptom·recurrence differences

New Understanding of Gardnerella Dominance

Old: Gardnerella dominant = BV = antibiotics

VIRGO2/VISTA:

  • Some Gardnerella types = non-inflammatory·asymptomatic
  • Similar stability to Lactobacillus
  • Other Gardnerella types = inflammatory·BV symptomatic
  • Strain differences in same species → clinical differences

Clinical:

  • Gardnerella detection ≠ automatic BV diagnosis
  • Strain-level classification needed
  • ↓ antibiotic overuse
  • Recurrence pattern prediction

BV Clinical Burden

Prevalence:

  • ~25% adult women
  • Reproductive age common
  • 50%+ recurrence

Symptoms: Gray discharge, malodor, itching·irritation

Risk factors: Antibiotic use, frequent sex, hormonal changes

Associated risks: ↑ preterm birth, ↑ STI infection, fertility clinic admissions ↑

L70 New Dimension - Precision Microbiome

L64 Yale microbiome (gut-estrogen 7x): Gut microbes·estrobolome, post-menopause hormones L67 Imperial metabolome (gut-cardiovascular 3-year prediction): Gut metabolites·cardiovascular L70 VIRGO2/VISTA (vaginal 25 types): Site-specific microbiome, strain-level precision

Women’s site-specific microbiome → precision medicine tool.

Korean Clinical Implications

Current Korea: Standard diagnosis = microscopy·NEDDII·Amsel criteria. BV drugs = metronidazole·clindamycin. 50%+ recurrence. Strain-level testing absent.

VIRGO2/VISTA adoption potential:

  • Sequencing cost ↓ ($100~$300)
  • Some OB-GYN starting
  • BV recurrence patients precision classification
  • Non-antibiotic options (probiotics·diet)

Self-Management - Strain-Level

Maintain Lactobacillus dominance (good):

  • Probiotics (LP 14P·CO 21·Bifidobacterium) 10¹⁰~10¹¹ CFU/day
  • Fermented dairy (yogurt·kefir)
  • Fiber (gut-vaginal axis)

Gardnerella dominance (precision needed):

  • Asymptomatic = possible non-inflammatory
  • Symptomatic = BV antibiotics
  • Doctor·strain test for distinction

Risk avoidance: Irritant soap·excessive cleanser avoid, ↓ stress, hormonal balance (peri/post-menopause)

Future - Precision BV Treatment

Existing BV treatment: Metronidazole 7 days (50% recurrence), clindamycin, lactobacillus supplements (inconsistent)

Future (5~10 yr):

  • Strain test → non-inflammatory/inflammatory
  • Targeted strain supplementation
  • FMT-like vaginal microbiome transplant (FemBio·Lyme research)
  • Antibiotic sparing (non-inflammatory = monitoring only)

FAQ

Q. BV diagnosed but might be non-inflammatory? A. Possible. Strain-level testing (some Korea), recurrence pattern, symptom severity - consult doctor. Good antibiotic response with frequent recurrence = possible non-inflammatory.

Q. Lactobacillus supplements effective? A. Consistent effect = strain-dependent (L. crispatus IPLA88·L. rhamnosus GR-1 specific strains). Generic probiotics insufficient.

Q. Post-menopause vaginal microbiome? A. Estrogen ↓ → Lactobacillus dominance ↓ + diversity ↑. Atrophic vaginitis risk. Hormone·topical estrogen cream consult.

Conclusion

VIRGO2/VISTA brings vaginal microbiome into 25-type strain-level precision classification. Gardnerella dominance ≠ automatic BV opens ↓ antibiotic overuse·recurrence prediction. L70 = 35 pillars + site-specific precision microbiome. After gut (L64 Yale)·cardiovascular (L67 Imperial), vaginal (L70 VIRGO2) precision microbiome era. Korea adoption beginning.

Source: UMD School of Medicine / mBio